These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25301077)

  • 1. Plasma CX3CL1 levels and long term outcomes of patients with atrial fibrillation: the West Birmingham Atrial Fibrillation Project.
    Guo Y; Apostalakis S; Blann AD; Lip GY
    Cerebrovasc Dis; 2014; 38(3):204-11. PubMed ID: 25301077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
    Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
    Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
    Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Osborne JS; Lappé DL; Bunch TJ
    Pacing Clin Electrophysiol; 2009 Aug; 32(8):981-6. PubMed ID: 19659615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation.
    Maehama T; Okura H; Imai K; Yamada R; Obase K; Saito K; Hayashida A; Neishi Y; Kawamoto T; Yoshida K
    Am J Cardiol; 2010 Aug; 106(4):535-8. PubMed ID: 20691312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation.
    Krishnamoorthy S; Khoo CW; Lim HS; Lane DA; Pignatelli P; Basili S; Violi F; Lip GY
    Eur J Clin Invest; 2013 Oct; 43(10):1032-8. PubMed ID: 23961715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
    Winkel TA; Hoeks SE; Schouten O; Zeymer U; Limbourg T; Baumgartner I; Bhatt DL; Steg PG; Goto S; Röther J; Cacoub PP; Verhagen HJ; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2010 Jul; 40(1):9-16. PubMed ID: 20385507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation.
    Roldán V; Marín F; García-Herola A; Lip GY
    Thromb Res; 2005; 116(4):321-5. PubMed ID: 16038717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of the CHADS
    Tabata N; Yamamoto E; Hokimoto S; Yamashita T; Sueta D; Takashio S; Arima Y; Izumiya Y; Kojima S; Kaikita K; Matsui K; Fujimoto K; Sakamoto K; Shimomura H; Tsunoda R; Hirose T; Nakamura N; Sakaino N; Nakamura S; Yamamoto N; Matsumura T; Kajiwara I; Koide S; Sakamoto T; Nakao K; Oshima S; Tsujita K;
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation.
    Ntaios G; Lip GY; Makaritsis K; Papavasileiou V; Vemmou A; Koroboki E; Savvari P; Manios E; Milionis H; Vemmos K
    Neurology; 2013 Mar; 80(11):1009-17. PubMed ID: 23408865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
    Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
    J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
    Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
    J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.
    Su HM; Lin TH; Hsu PC; Lee WH; Chu CY; Lee CS; Voon WC; Lai WT; Sheu SH
    Heart; 2013 Nov; 99(21):1588-96. PubMed ID: 24014280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GY
    J Am Coll Cardiol; 2013 May; 61(20):2079-87. PubMed ID: 23524209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.